A groundbreaking patent pending platform for early cancer detection

The GlycoLocate™ Platform is the future

Tumor marker gangliosides are a novel class of biomarkers. Originating in tumor tissue, these targets are stable and present throughout cancer formation, development, and relapse. Given their persistent and homogeneous expression almost exclusively in cancer, tumor marker gangliosides are promising targets to be exploited as biomarkers.

AOA Dx is pioneering the field of glycolipids

The GlycoLocate™ platform will be the first of its kind to use tumor marker gangliosides as biomarkers to diagnose early-stage cancers by using a non-invasive blood test.

Early cancer detection,

Our AI-enabled GlycoLocate™ platform will be the first and only to harnesses the power of tumor marker gangliosides to detect cancer earlier, enabling more patients to get access to life-saving treatments sooner. The GlycoLocate™ platform can differentiate between cancers down to their tissue of origin in both symptomatic and non-symptomatic patients. This superior breakthrough technology removes the typical barriers of cost, invasiveness, accessibility, and effectiveness seen with current early detection technologies.

Glycomics of tumor marker gangliosides are the next frontier in early cancer detection

To date, genomics and proteomics have been used as tools in precision medicine. The active role of tumor marker gangliosides during cancer development makes them specific and etiological biomarkers of malignancy. AOA Dx foresees glycomics of tumor marker gangliosides as the next frontier used for diagnosis, prognosis, monitoring and ultimately targeted therapies. Identification of markers through the GlycoLocate™ platform will allow earlier and more accurate detection of cancer, changing the paradigm of early cancer detection.

Ovarian cancer is just the start for AOA Dx and the GlycoLocate™ platform

Developing the platform in collaboration with leading world experts and scientists in conjunction with state-of-the-art data science, we believe we can change the paradigm of early diagnosis of many of the world’s deadliest cancers.

The GylcoLocate™ platform is changing the world of cancer detection to diagnose patients earlier and keep them with their loved ones longer. Find out how AKRIVIS GD™ is transforming women’s health through early ovarian cancer detection